Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Johnson and Johnson
Medtronic
McKinsey
Merck

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR PORFIMER SODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Porfimer Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002647 ↗ Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status Medical College of Wisconsin Phase 1 1994-05-01 RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and may be an effective treatment for refractory brain tumors. PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic therapy using porfimer sodium in treating patients with refractory brain tumors, including astrocytoma, ependymoma, and medulloblastoma.
NCT00002935 ↗ Photodynamic Therapy in Treating Patients With Early Esophageal Cancer Completed Roswell Park Cancer Institute Phase 2 1995-10-01 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective treatment for esophageal cancer. PURPOSE: Phase II trial to study the effectiveness of photodynamic therapy in treating patients with Barrett's esophagus who have in situ esophageal cancer.
NCT00002964 ↗ Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer Completed Roswell Park Cancer Institute Phase 2 1995-02-01 RATIONALE: Drugs that make cancer cells more visible to light may help in the diagnosis of head and neck cancer. PURPOSE: Phase II trial to study the usefulness of porfimer sodium in diagnosing patients with head and neck cancer.
NCT00003788 ↗ Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status Colorado Health Foundation Phase 3 1998-04-01 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. It is not yet known if the addition of photodynamic therapy to combined therapy with surgery, radiation therapy, and chemotherapy is more effective than combined therapy alone for supratentorial gliomas. PURPOSE: Randomized phase III trial to study the effectiveness of surgery, radiation therapy, and chemotherapy with or without photodynamic therapy in treating patients who have newly diagnosed or recurrent malignant supratentorial gliomas.
NCT00003923 ↗ Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Completed National Cancer Institute (NCI) Phase 2 1999-03-01 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas. PURPOSE: Phase II trial to determine the effectiveness of photodynamic therapy in treating patients who have cancer of the bile duct, gallbladder, or pancreas.
NCT00003923 ↗ Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Completed Memorial Sloan Kettering Cancer Center Phase 2 1999-03-01 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas. PURPOSE: Phase II trial to determine the effectiveness of photodynamic therapy in treating patients who have cancer of the bile duct, gallbladder, or pancreas.
NCT00054002 ↗ Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma Completed Roswell Park Cancer Institute Phase 2 1999-03-01 RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Combining photodynamic therapy with surgery may be an effective treatment for malignant mesothelioma. PURPOSE: Phase II trial to study the effectiveness of combining photodynamic therapy with surgery in treating patients who have malignant mesothelioma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Porfimer Sodium

Condition Name

Condition Name for Porfimer Sodium
Intervention Trials
Brain and Central Nervous System Tumors 3
Lung Cancer 3
Head and Neck Cancer 3
Metastatic Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Porfimer Sodium
Intervention Trials
Lung Neoplasms 9
Carcinoma, Non-Small-Cell Lung 8
Mesothelioma, Malignant 5
Mesothelioma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Porfimer Sodium

Trials by Country

Trials by Country for Porfimer Sodium
Location Trials
United States 51
Canada 5
Korea, Republic of 4
Germany 4
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Porfimer Sodium
Location Trials
New York 13
Pennsylvania 5
Florida 4
Wisconsin 3
Washington 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Porfimer Sodium

Clinical Trial Phase

Clinical Trial Phase for Porfimer Sodium
Clinical Trial Phase Trials
Phase 3 5
Phase 2 13
Phase 1/Phase 2 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Porfimer Sodium
Clinical Trial Phase Trials
Completed 15
Terminated 6
Recruiting 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Porfimer Sodium

Sponsor Name

Sponsor Name for Porfimer Sodium
Sponsor Trials
Roswell Park Cancer Institute 9
National Cancer Institute (NCI) 9
Pinnacle Biologics Inc. 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Porfimer Sodium
Sponsor Trials
Other 33
Industry 11
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Medtronic
Harvard Business School
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.